Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2026-01-01 @ 2:27 AM
Study NCT ID:
NCT04704934
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-10
First Post:
2021-01-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Sponsor:
Daiichi Sankyo
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-21
Start Date Type:
ACTUAL
Primary Completion Date:
2026-08-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-08-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-01-08
First Submit QC Date:
None
Study First Post Date:
2021-01-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-07
Last Update Post Date:
2025-11-10
Last Update Post Date Type:
ESTIMATED